Caldera Therapeutics reports new CLD-423 Phase 1a data, expands pipeline with anti IL-17 X TL1A bispecific antibody program

Caldera Therapeutics reports new Phase 1a data for CLD-423 and expands its immunology and inflammation pipeline with an anti IL-17 X TL1A bispecific antibody program.

Detected & updated continuously · Source: Nebula